Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. News about Spero often centers on its lead investigational product, tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem antibiotic candidate for complicated urinary tract infections (cUTI), including pyelonephritis.
Readers following SPRO news can expect updates on clinical trial milestones, such as the pivotal Phase 3 PIVOT-PO trial, which Spero and its partner GSK reported met its primary endpoint and was stopped early for efficacy. Coverage also includes presentations of clinical data at major infectious disease conferences like IDWeek, where late-breaking results and detailed efficacy and safety analyses for tebipenem HBr have been shared.
Spero’s news flow also features regulatory and partnership developments. This includes announcements that GSK plans to, and has, submitted or resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for tebipenem HBr in cUTI, including pyelonephritis, as well as disclosures about milestone payments to Spero triggered by these filings under the exclusive license agreement between the companies.
In addition, Spero regularly reports its quarterly operating results and business updates, detailing collaboration revenue, grant funding, research and development spending, and cash runway expectations. Corporate governance and capital markets news, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), amendments to stock incentive plans, and outcomes of annual stockholder meetings, also appear in the company’s announcements.
For investors, clinicians, and observers interested in antibiotic development, MDR infections, and rare disease therapeutics, the SPRO news page provides a consolidated view of Spero’s clinical progress, regulatory interactions, financial updates, and key collaborations over time.
Spero Therapeutics (Nasdaq: SPRO) will present a corporate update at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:00 a.m. ET. The presentation will be led by Ankit Mahadevia, M.D., President and CEO. Interested individuals can access the webcast on Spero's website under the 'Events and Presentations' section. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, including its lead product candidate, tebipenem HBr, aimed at treating MDR Gram-negative infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 1, 2020, the grant of stock options totaling 29,500 shares to four new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $11.82 per share, vest over four years, incentivizing employee retention. This grant aligns with Nasdaq Listing Rule 5635(c)(4), allowing equity awards to non-employees as a recruitment tool. Spero focuses on treating multi-drug resistant infections and rare diseases, advancing key candidates like tebipenem HBr for MDR infections and SPR720 for a rare disease associated with NTM.
Spero Therapeutics (Nasdaq: SPRO) has completed enrollment in its pivotal Phase 3 ADAPT-PO trial for tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) in approximately 1,370 patients. Top-line results are expected in Q3 2020. The company also plans to initiate a Phase 2a trial for SPR720, targeting non-tuberculous mycobacterial disease. Financially, Spero reported a Q1 2020 net loss of $23.3 million, significantly higher than the $5.1 million loss in Q1 2019. Total revenue dropped to $1.7 million from $7.7 million in the prior year due to reduced funding and collaboration revenue.
Spero Therapeutics (Nasdaq: SPRO) announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, for tebipenem HBr, targeting complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). This milestone involves over 1,370 subjects and aims to compare an oral regimen of tebipenem HBr against standard intravenous treatment. The company expects to report topline results in Q3 2020, emphasizing the unmet need for effective oral therapies to reduce hospitalizations caused by drug-resistant infections.
Summary not available.